unknown
Stage
About
Cellectar Biosciences develops targeted cancer therapies using its Phospholipid Drug Conjugate (PDC) platform to deliver therapeutic agents directly to tumor cells, aiming to maximize antitumor activity while minimizing off-target effects.
Explore Cellectar Biosciences, Inc.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.